Incannex Healthcare: Disrupting the obstructive sleep apnoea space with IHL-42

Incannex Healthcare: Disrupting the obstructive sleep apnoea space with IHL-42

Associated equity: Incannex Healthcare

Incannex Healthcare is an Australian dual-listed biotech company focused on developing medicinal cannabis pharmaceutical products and psychedelic medicine therapies. These therapies are being designed to target indications with unmet need, including obstructive sleep apnea, generalized anxiety disorder, trauma and inflammatory conditions.

Incannex Healthcare — 1 video in collection

Incannex Healthcare (Nasdaq: IXHL, ASX: IHL) is an Australian biotech specialising in the development of treatments for chronic conditions using cannabinoids and psychedelic therapies.

Incannex has 28 clinical programmes in progress and holds one of the world’s largest portfolios of patented cannabinoid drug formulations and psychedelic treatment regimes.

The company’s most advanced clinical asset, IHL-42X, is being developed for the treatment of obstructive sleep apnoea and will see bioavailability and bioequivalence studies roll out in 2023.

Watch Dr Mark Bleackley, Incannex’s chief scientific officer, and Joel Latham, the company’s MD and CEO, being interviewed by Vivienne Parry, to find out more about IHL-42X and Incannex Healthcare’s investment case.

You may also be interested in these:


Executive interview: Volition FY22 earnings


Basilea Pharmaceutica – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free